Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

pembrolizumab 2Etoposide 2Cyclophosphamide 2talimogene laherparepvec 1romidepsin 1prednylidene 1fludarabine phosphate 1etoposide phosphate 1entrectinib 1deltacortene 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1Sirolimus 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Maintenance 1Lactones 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Doxorubicin 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large-Cell, Anaplastic × pembrolizumab × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡